Canada's Monteris Medical announced a $30 million equity financing for its NeuroBlate robotic neurosurgical system to ablate, or destroy using heat, brain lesions like primary and metastatic tumors.
After putting up evidence to show that the liver toxicity triggered by its lead drug can be reversed, the FDA has lifted the full hold placed on its lead--and only--cancer drug. And investors responded enthusiastically to the biotech's return to the clinic, boosting shares by 35% in premarket trading.
Researchers in California believe they've zeroed in on biomarkers--microRNAs--that will help determine who will respond best to the treatment and help boost its success rate.
Patients with a lethal form of brain cancer lived nearly twice as long as expected after receiving Agenus' ($AGEN) Prophage vaccine in a Phase II study, according to the company.
The cancer vaccine field has seen its share of late-stage disappointments and outright flops, but a number of hopefuls are lining up to present new research backing their experimental shots at this year's upcoming American Society of Clinical Oncology Annual Meeting in Chicago.
A pair of biotechs will proceed with cancer vaccine studies thanks to recent recommendations from data-monitoring committees. Their announcements drew mixed results from investors, with Northwest Biotherapeutics' shares soaring and NewLink Genetics' sinking. But as they forge ahead, both companies will have to shake off the looming specters of failed cancer vaccine trials past.
Northwest Biotherapeutics announced that German health regulators have OK'd a special hospital exemption that allows the sale of its controversial--and unproven--dendritic vaccine for brain cancer for all glioma brain cancers.
Bethesda, MD's Northwest Biotherapeutics has watched as rivals Dendreon and ImmunoCellular have run into serious roadblocks with personalized cancer vaccines over the past year, but with a major Phase III study underway, the biotech believes it can change the narrative.
Should Avastin really join the small set of tools in the brain-cancer toolbox? With studies offering conflicting results, Roche and some outside researchers may share data to answer that question.
Agenus has fallen a long way since its stock briefly traded for $300 a share in 2000. The failure of its partner GlaxoSmithKline's cancer vaccine in September sent the stock tumbling 23% to $2.84 and it continued to drop in the following months. Now though, Agenus has good news to report.